Suppr超能文献

儿童肌张力障碍

Childhood dystonias.

作者信息

Tabbal Samer D

机构信息

Department of Neurology, American University of Beirut, Riad El-Solh, PO Box 11-0236, Beirut, 1107 2020, Lebanon,

出版信息

Curr Treat Options Neurol. 2015 Mar;17(3):339. doi: 10.1007/s11940-015-0339-4.

Abstract

Dystonia is a movement disorder caused by diverse etiologies. Its treatment in children is particularly challenging due to the complexity of the development of the nervous system from birth to young adulthood. The treatment options of childhood dystonia include several oral pharmaceutical agents, botulinum toxin injections, and deep brain stimulation (DBS) therapy. The choice of drug therapy relies on the suspected etiology of the dystonia and the adverse effect profile of the drugs. Dystonic syndromes with known etiologies may require specific interventions, but most dystonias are treated by trying serially a handful of medications starting with those with the best risk/benefit profile. In conjunction to drug therapy, botulinum toxin injections may be used to target a problematic group dystonic muscles. The maximal botulinum toxin dose is limited by the weight of the child, therefore limiting the number of the muscles amenable to such treatment. When drugs and botulinum toxin injections fail to control the child's disabling dystonia, DBS therapy may be offered as a last remedy. Delivering optimal DBS therapy to children with dystonia requires a multidisciplinary team of experienced pediatric neurosurgeons, neurologists, and nurses to select adequate candidates, perform this delicate stereotactic procedure, and optimize DBS delivery. Even in the best hands, the response of childhood dystonia to DBS therapy varies greatly. Future therapy of childhood dystonia will parallel the advancement of knowledge of the pathophysiology of dystonic syndromes and the development of clinical and research tools for their study.

摘要

肌张力障碍是一种由多种病因引起的运动障碍。由于从出生到成年早期神经系统发育的复杂性,其在儿童中的治疗尤其具有挑战性。儿童肌张力障碍的治疗选择包括几种口服药物、肉毒杆菌毒素注射和深部脑刺激(DBS)疗法。药物治疗的选择取决于肌张力障碍的疑似病因和药物的不良反应情况。已知病因的肌张力障碍综合征可能需要特定的干预措施,但大多数肌张力障碍是通过从风险/效益比最佳的药物开始,依次尝试几种药物来治疗的。除药物治疗外,肉毒杆菌毒素注射可用于针对一组有问题的肌张力障碍肌肉。肉毒杆菌毒素的最大剂量受儿童体重限制,因此限制了可接受这种治疗的肌肉数量。当药物和肉毒杆菌毒素注射无法控制儿童致残性肌张力障碍时,DBS疗法可作为最后的治疗手段。为患有肌张力障碍的儿童提供最佳的DBS疗法需要一个由经验丰富的儿科神经外科医生、神经科医生和护士组成的多学科团队,以选择合适的候选人、进行这种精细的立体定向手术并优化DBS治疗。即使在最有经验的医生手中,儿童肌张力障碍对DBS疗法的反应也有很大差异。儿童肌张力障碍的未来治疗将与肌张力障碍综合征病理生理学知识的进步以及用于其研究的临床和研究工具的发展同步。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验